Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | $5,054.8M | $4,528.0M | $5,891.4M | $6,012.0M | $5,776.0M | $2,937.0M | $7,003.0M | $6,562.0M | $9,431.0M | $12.8B | $12.8B | $16.8B | $22.0B | $24.2B | $22.1B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, AbbVie Inc.'s last 12-month Free Cash Flow is $15.6B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, AbbVie Inc.'s Free Cash Flow growth was (36.8%). The average annual Free Cash Flow growth rates for AbbVie Inc. have been (4.2%) over the past three years, 3.9% over the past five years.
Over the last year, AbbVie Inc.'s Free Cash Flow growth was (36.8%), which is lower than industry growth of (0.2%). It indicates that AbbVie Inc.'s Free Cash Flow growth is Bad.